kr190.35
0.78% yesterday
Copenhagen, Dec 05, 04:59 pm CET
ISIN
DK0015998017
Symbol
BAVA

Bavarian Nordic Stock price

kr190.35
-45.65 19.34% 1M
+9.95 5.52% 6M
+1.00 0.53% YTD
-2.20 1.14% 1Y
-45.25 19.21% 3Y
+6.65 3.62% 5Y
-143.65 43.01% 10Y
-297.15 60.95% 20Y
Copenhagen, Closing price Fri, Dec 05 2025
-1.50 0.78%
ISIN
DK0015998017
Symbol
BAVA
Industry

New AI Insights on Bavarian Nordic Insights AI Insights on Bavarian Nordic

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
kr15.2b
Enterprise Value
kr12.3b
Net debt
positive
Cash
kr3.0b
Shares outstanding
78.3m
Valuation (TTM | estimate)
P/E
6.2 | 16.2
P/S
2.2 | 2.4
EV/Sales
1.8 | 1.9
EV/FCF
9.6
P/B
1.2
Financial Health
Equity Ratio
79.2%
Return on Equity
8.7%
ROCE
18.7%
ROIC
22.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
kr6.9b | kr6.3b
EBITDA
kr3.2b | kr1.9b
EBIT
kr2.5b | kr1.2b
Net Income
kr2.4b | kr918.1m
Free Cash Flow
kr1.3b
Growth (TTM | estimate)
Revenue
13.5% | 10.9%
EBITDA
82.3% | 84.5%
EBIT
118.1% | 31.8%
Net Income
118.6% | -7.1%
Free Cash Flow
360.1%
Margin (TTM | estimate)
Gross
54.3%
EBITDA
46.4% | 29.7%
EBIT
36.2%
Net
35.5% | 14.5%
Free Cash Flow
18.6%
More
EPS
kr30.7
FCF per Share
kr16.4
Short interest
-
Employees
2k
Rev per Employee
kr3.6m
Show more

Is Bavarian Nordic a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Bavarian Nordic Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Bavarian Nordic forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a Bavarian Nordic forecast:

Buy
67%
Hold
33%

Financial data from Bavarian Nordic

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
6,887 6,887
13% 13%
100%
- Direct Costs 3,146 3,146
9% 9%
46%
3,741 3,741
18% 18%
54%
- Selling and Administrative Expenses 1,256 1,256
30% 30%
18%
- Research and Development Expense 802 802
27% 27%
12%
3,198 3,198
82% 82%
46%
- Depreciation and Amortization 705 705
15% 15%
10%
EBIT (Operating Income) EBIT 2,494 2,494
118% 118%
36%
Net Profit 2,445 2,445
119% 119%
36%

In millions DKK.

Don't miss a Thing! We will send you all news about Bavarian Nordic directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Head office Denmark
CEO Paul Chaplin
Employees 1,605
Founded 1992
Website www.bavarian-nordic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today